Maxwell Biotech Venture Fund
Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF relies on an experienced international team of managers and financial and industry experts and has offices in Moscow and Boston. To date, MBVF has invested in 9 life science companies. The fund manages an investment portfolio of around $100 million.
German High-Tech Gründerfonds invests venture capital in young technology companies with promising research results and strong potential to enable then to transform innovative ideas into entrepreneurial success. Seed financing helps startups take their R&D projects to the prototype, “proof-of-concept” or market launch phases. The public-private partnership investors include the German Federal Ministry of Economics and Technology, the KfW Banking Group alongside the 18 corporate investors ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE Color, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligung, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gründerfonds manages a total investment portfolio of around €576 million (€272m Fonds I and €304m Fonds II).
In addition to the license agreement, MYR has a collaboration and research agreement with the University Clinic Heidelberg, one of Germany`s most renowned academical centers for biomedical research. Large parts of the non-clinical development and the human Phase 1 trial were performed in Heidelberg. Additional clinical trials with participation of the University Hospital Heidelberg are planed.
MYR has licensed CIS rights for Myrcludex B to Hepatera, who is now conducting the development program with the aim of registration of the drug in CIS countries. The results of the studies will be used as part of the international development effort undertaken by MYR.